- Home
- AGIO
as 02-21-2025 4:00pm EST
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 2.0B | IPO Year: | 2013 |
| Target Price: | $56.33 | AVG Volume (30 days): | 621.1K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 11.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $27.14 - $62.58 | Next Earning Date: | 02-13-2025 |
| Revenue: | $36,498,000 | Revenue Growth: | 36.07% |
| Revenue Growth (this year): | 166.22% | Revenue Growth (next year): | 98.36% |
Stock Insider Trading Activity of Agios Pharmaceuticals Inc. (AGIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Washburn Theodore James Jr. | AGIO | Principal Accounting Officer | Feb 1 '25 | Sell | $34.39 | 2,272 | $78,134.08 | 5,437 | |
| Milanova Tsveta | AGIO | Chief Commercial Officer | Jan 3 '25 | Sell | $32.18 | 2,804 | $90,232.72 | 18,906 | |
| Scadden David | AGIO | Director | Dec 11 '24 | Sell | $46.28 | 200 | $9,256.00 | 15,483 |
Latest Agios Pharmaceuticals Inc. News
AGIO Breaking Stock News: Dive into AGIO Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025
TipRanks
7 days ago
Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank
Zacks
8 days ago
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues
Simply Wall St.
8 days ago
Agios Pharmaceuticals Full Year 2024 Earnings: Beats Expectations
GuruFocus.com
8 days ago
Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...
Benzinga
9 days ago
Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years
Zacks
9 days ago
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates
MT Newswires
9 days ago
Agios Pharmaceuticals' Q4 Loss Widens, Revenue Rises
Compare AGIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AGIO Agios Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.